AMAG appoints chief development and regulatory officer
This article was originally published in Scrip
AMAG Pharmaceuticals, which markets an intravenous iron products in the US for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD), has named Dr Steven Caffé senior vice-president and chief development and regulatory officer. He joins the Lexington, Massachusetts-based company from MedImmune, AstraZeneca's global biologics research and development arm, where he was senior-vice president of global regulatory affairs and patient safety.
You may also be interested in...
Diversity in all forms is critical to innovation in health care, says AstraZeneca’s chief medical officer, Ann Taylor. In an exclusive interview, she talks about the company’s work in mentoring and education, and why tackling issues around diversity and inclusion must be driven by the C-suite alongside community initiatives.
A selection of articles you might have missed from October 2020, including exclusive interviews with industry leaders and a deeper dive into the Femtech market.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.